



Full-Service Biomarker Assay Development

Scientific Excellence. Regulatory Confidence. Purpose-Built Strategies.

Biomarkers are increasingly essential to de-risking drug development and accelerating therapeutic programs. Eurofins Viracor BioPharma provides industry-leading expertise in large-molecule bioanalysis, delivering robust, decision-ready biomarker data across all phases of development.

Our team applies deep scientific knowledge and a platform-agnostic approach to ensure every biomarker method is optimized for performance, regulatory alignment, and program strategy.

Accelerate confident decision-making with biomarker solutions built for scientific rigor, regulatory readiness, and operational speed.

We deliver end-to-end assay development and analysis grounded in decades of experience, a broad suite of analytical technologies, and collaborative consultation that ensures each assay is only as complex, sensitive, and robust as it needs to be.

The Eurofins Advantage in Biomarker Analysis Unmatched Scientific and Regulatory Expertise

With more than 20 years of global bioanalytical leadership, our scientists bring industry-leading experience across PK/TK, ADA, NAb, and biomarker assay development. We deliver high-quality data aligned with the latest regulatory guidance and industry best practices.

Technology Platforms – Applied with Precision

Eurofins offers one of the broadest biomarker technology portfolios in the industry, enabling true fit-for-purpose method selection. Our platform expertise includes:

- Luminex®
- MSD®
- QuantStudio™ 7 Flex (qPCR)
- Novocyte Quanteon™
- ImmunoSpot® S6 Entry M2

By selecting the best platform for each analyte and study design, we ensure analytical reliability, sample integrity, and efficient turnaround times.



Fit-for-Purpose Assay Strategy

We employ a disciplined, scientifically grounded “fit-for-purpose” approach to qualification and validation. Assays are designed to meet program requirements—no more, no less—balancing accuracy, sensitivity, and operational efficiency.



Consultative Partnership

Our experts engage early and often, offering scientific consultation, method troubleshooting, and strategic guidance throughout development. Every study benefits from hands-on project management and proactive communication.



Comprehensive Exploratory Through Regulated Support

From early discovery to pivotal clinical trials, we support single-plex and multiplex assays, custom method development, and fully compliant GxP validations tailored to regulatory submissions.



Advanced Facility with Scalable Capacity

Our state-of-the-art laboratory in Lenexa, KS provides high throughput, global reach, and flexible capacity to support biomarker testing for programs of all sizes.



Biomarker Service Offerings

"Fit-for-Purpose" Biomarker Analysis

- Consultation and scientific guidance for assay development and validation
- "Fit-for-purpose" qualification and validation across all bioanalytical assays
- Full GxP compliance
- Extensive experience contributing to industry guidelines
- Single-plex and multiplex assay development and analysis
- Validation for regulatory submissions
- Comprehensive assay validation or cross-validation services

Exploratory Biomarker Services

- Expertise in complex assays across diverse platforms and matrices
- Rapid implementation with commercially available kits
- Portability and expedited solutions for early decision-making
- Flexible assay development for exploratory endpoints

qPCR

- Gene expression analysis
- SNP genotyping analysis
- Biodistribution and vector shedding assessments
- Assay development, qualification, and validation

Flow Cytometry Services

- More than 20 years of experience in custom assay development and sample processing
- Sophisticated consultation for multi-site clinical trials
- Multi-color surface phenotyping and intracellular analysis
- Target engagement and receptor occupancy assays
- Functional assessments including ADCC and related mechanisms

Biomarker Resources



WEBSITE RESOURCE
Biomarker Menu



ARTICLE
Optimizing Clinically Actionable Biomarker Detection in Advanced Cancers by Next Generation Sequencing (NGS) Panel and Specimen Type



ARTICLE
Advancing Cancer Research: Qualification Studies of the nCounter PanCancer IO 360 Gene Expression Panel



SCIENTIFIC POSTER
Overcoming Challenges for Flow Cytometry in Clinical Regulated Biomarker Analysis



SCIENTIFIC POSTER
Validating Flow Cytometry Assays for Use During Clinical Trial Biomarker Assessments



Advance Your Biomarker Strategy with Confidence

Partner with Eurofins Viracor BioPharma to generate high-quality, decision-ready data that accelerates development.

Contact: clinicaltrials@vbp.eurofinsus.com

Visit: eurofinsvbp.com

Eurofins Viracor BioPharma
8035 Quivira Road Lenexa, KS 66214

